Alzheimer\'s disease (AD) is rapidly becoming a major public health threat with increasing numbers of affected individuals as the world\'s population ages. There are currently 5.3 million Americans and 35 million people worldwide with AD dementia, and the number will increase to nearly 15 million in the United States and over 100 million globally by 2050 if treatments are not found [@bib1], [@bib2].

New therapies are needed for this burgeoning population of affected and at-risk persons that improve the symptoms of patients with memory and cognitive decline, prevent or delay the onset of AD in individuals who are at-risk for the disease, or slow progression in those with declining cognition. New therapies are being assessed in clinical trials but the success rate of AD drug development has been low with the last new novel agent approved in 2003 [@bib3].

To gain insight into the current AD treatment pipeline, we reviewed all trials registered in [clinicaltrials.gov](http://clinicaltrials.gov){#intref0015} (accessed 1/4/2016), the US government website that lists all US and most global clinical trials. Registration of new trials on the site is required for trials approved by the US Food and Drug Administration (FDA) since 2007 [@bib4]. We reviewed this comprehensive website for all agents in clinical trials for AD dividing them into those in phase I, phase II, and phase III. The purpose of the study was to understand the landscape of AD drug development and determine evolutions occurring in AD drug development from historical practices. The goal is to assess the state of AD drug development, anticipate the emergence of new therapies, review emerging pharmacologic mechanisms and clinical trial approaches, and derive lessons possibly helpful in the drug development process.

1. Methods {#sec1}
==========

We interrogated [clinicaltrials.gov](http://clinicaltrials.gov){#intref0020} with the information summarized here accessed on January 4, 2016. We used the search features of the site to capture all agents listed for AD in phase I, II, and III. We captured the trial title, beginning date, anticipated ending date, anticipated duration, number of subjects to be enrolled, number of arms of the study (usually a placebo arm and one or more treatment arms with different doses of the test agent), whether a biomarker was described, and whether the sponsor was a biopharma company, the National Institutes of Health (NIH), a combination of biopharma and NIH, or "other." We included trials that were recruiting, active but not recruiting---trials that have completed recruiting and are continuing as the efficacy or safety of the agent is being determined---and enrolling by invitation. We did not include trials listed as not yet recruiting, completed, terminated, suspended, or withdrawn. These exclusions were based on our interest in the currently active pipeline and what agents could evolve in the near term. Reasons for terminating, suspending, or withdrawing trials are often not provided, and we could not draw conclusions about these trials or the agents involved. The agents and trials reviewed comprise a comprehensive list of agents currently in trials. The list is not exhaustive because not all non-US trials are registered on [clinicaltrials.gov](http://clinicaltrials.gov){#intref0025}, and there is sometimes a delay in registering trials. The mechanism of action of each agent was determined from the information on [clinicaltrials.gov](http://clinicaltrials.gov){#intref0030} (e.g., the mechanism is often noted in the title of the trial or in a description of the trial) or from a comprehensive search of the literature if the mechanism was not provided on the federal website. In a few cases, the mechanism is undisclosed. We grouped the mechanisms into symptomatic or disease modifying. We further divided the symptomatic agents into those that were putative cognitive-enhancing agents or those that addressed neuropsychiatric symptoms. Disease-modifying therapies (DMT) were divided into those that targeted amyloid-related targets, those that aimed at modifying tau-related mechanisms and those with "other" mechanisms such as neuroprotection or metabolic effects [@bib5]. The definitions of disease-modification and neuroprotection are controversial and evolving [@bib6], [@bib7]; the terminology is used here to conveniently classify the types of mechanisms for agents in current AD drug-development programs. We did not include nonpharmacologic therapeutic approaches such as devices, cognitive therapies, and medical foods.

2. Results {#sec2}
==========

There are currently 93 agents in some phase of drug development for AD. [Fig. 1](#fig1){ref-type="fig"} provides a comprehensive overview of the agents currently in clinical trials for AD.Fig. 1Agents currently in clinical trials for AD (shape indicates stage of disease of patients in the trials; color shows the mechanism of action; location shows phase of development and category of activity---immunotherapy, disease-modifying small molecule, symptom-reducing small molecule).

2.1. Phase III {#sec2.1}
--------------

There are 24 agents in 36 trials in phase III of AD drug development. Eight agents are in two or more clinical trials. Of the agents in trials, seven are symptomatic treatments targeting neurotransmitter pathways with cognitive enhancement (3) or neuropsychiatric (4) effects. Encenicline, a nicotinic cognitive-enhancing agent, was put on clinical hold by the FDA pending the review of gastrointestinal effects seen in some trial participants. Of the 17 DMTs in phase III, 12 are small molecules, and 5 are immunotherapies. All the immunotherapies and 8 of the 12 small molecules are directed at amyloid-related targets. There are four beta-site amyloid precursor protein cleaving enzyme (BACE) inhibitors in phase III trials. Amyloid-targeting agents comprise 76% of the late-stage DMT pipeline. There is one antitau agent in phase III---TRx0237.

The mean duration of trials of symptomatic agents was 23.3 weeks; the mean duration of DMT trials was 114.1 weeks. In these phase III trials, the mean number of subjects per arm for symptomatic trials is 392.2 and for trials of DMT agents is 516.1.

Eighty-eight percent (32 of 36) of trials are sponsored by the biopharma industry, 2 are jointly sponsored by NIH and industry, and 2 are sponsored by "other" entities.

[Table 1](#tbl1){ref-type="table"} shows the agents in phase III with their mechanism of action.Table 1Agents currently in phase III of development and their mechanism of action (as of 1/4/2016)AgentAgent mechanism classMechanism of actionClinicaltrials.gov IDSponsorStart dateEstimated end dateAC-1204MetabolicKetogenic agent[NCT01741194](ctgov:NCT01741194){#intref0070}AcceraMar 13Oct 17AducanumabAntiamyloidMonoclonal antibody[NCT02484547](ctgov:NCT02484547){#intref0075}BiogenSep 15Feb 22[NCT02477800](ctgov:NCT02477800){#intref0080}BiogenAug 15Feb 22Albumin + ImmunoglobulinAntiamyloidPolyclonal antibody[NCT01561053](ctgov:NCT01561053){#intref0085}Instituto Grifols, S.A.Mar 12Dec 16ALZT-OP1a + ALZT-OP1bAntiamyloidAntiamyloid combination (undisclosed target)[NCT02547818](ctgov:NCT02547818){#intref0090}AZTherapiesSep 15Mar 18AripiprazoleNeurotransmitter basedAtypical anti-psychotic[NCT02168920](ctgov:NCT02168920){#intref0095}OtsukaJun 14Jul 17AVP-786Neurotransmitter basedMixed transmitter effect[NCT02442765](ctgov:NCT02442765){#intref0100}AvanirSep 15Jul 18[NCT02446132](ctgov:NCT02446132){#intref0105}AvanirDec 15Jul 19AZD3293AntiamyloidBACE inhibitor[NCT02245737](ctgov:NCT02245737){#intref0110}AstraZenecaSep 14May 19Brexpiprazole (OPC-34712)Neurotransmitter basedAtypical anti-psychotic[NCT01862640](ctgov:NCT01862640){#intref0115}OtsukaJul 13Jun 17[NCT01922258](ctgov:NCT01922258){#intref0120}OtsukaSep 13Jun 17CAD106Anti-amyloidAmyloid vaccine[NCT02565511](ctgov:NCT02565511){#intref0125}NovartisNov 15Aug 23CNP520Anti-amyloidBACE inhibitor[NCT02565511](ctgov:NCT02565511){#intref0130}NovartisNov 15Aug 23GantenerumabAnti-amyloidMonoclonal antibody[NCT02051608](ctgov:NCT02051608){#intref0135}Hoffmann-La RocheMar 14Mar 19[NCT01224106](ctgov:NCT01224106){#intref0140}Hoffmann-La RocheNov 10Oct 20[NCT01760005](ctgov:NCT01760005){#intref0145}[∗](#tbl1fnlowast){ref-type="table-fn"}Washington University School of MedicineDec 12Dec 19Idalopirdine (Lu AE58054)Neurotransmitter based5-HT6 antagonist[NCT02079246](ctgov:NCT02079246){#intref0150}H. Lundbeck A/SApr 14Oct 17[NCT02006654](ctgov:NCT02006654){#intref0155}H. Lundbeck A/SMar 14Mar 17[NCT02006641](ctgov:NCT02006641){#intref0160}H. Lundbeck A/SFeb 14Mar 17[NCT01955161](ctgov:NCT01955161){#intref0165}H. Lundbeck A/SOct 13Oct 16Insulin (Humulin)MetabolicMetabolic agent[NCT01767909](ctgov:NCT01767909){#intref0170}University of Southern CaliforniaSep 13Feb 17JNJ-54861911Anti-amyloidBACE inhibitor[NCT02569398](ctgov:NCT02569398){#intref0175}JanssenOct 15May 23MasitinibAnti-inflammatory, neuroprotectiveTyrosine kinase inhibitor[NCT01872598](ctgov:NCT01872598){#intref0180}AB ScienceJan 12Dec 16MK-8931 (Verubecestat)Anti-amyloidBACE inhibitor[NCT01953601](ctgov:NCT01953601){#intref0185}Merck Sharp & Dohme Corp.Nov 13Mar 21NabiloneNeurotransmitter basedCannabinoid (receptor agent)[NCT02351882](ctgov:NCT02351882){#intref0190}Sunnybrook Health Sciences CentreJan 15Dec 17NilvadipineAnti-amyloidCalcium channel blocker[NCT02017340](ctgov:NCT02017340){#intref0195}St. James\'s Hospital, IrelandOct 12Dec 17PioglitazoneMetabolicPPAR-gamma agonist; anti-amyloid effect[NCT02284906](ctgov:NCT02284906){#intref0200}TakedaFeb 15Apr 21[NCT01931566](ctgov:NCT01931566){#intref0205}TakedaAug 13Jul 19RVT-101Neurotransmitter based5-HT6 antagonist[NCT02585934](ctgov:NCT02585934){#intref0210}Axovant SciencesOct 15Oct 17Sodium oligo-mannurarate (GV-971)Anti-amyloidAnti-amyloid agent[NCT02293915](ctgov:NCT02293915){#intref0215}Shanghai Greenvalley Pharmaceutical Co., Ltd.Apr 14May 17SolanezumabAnti-amyloidMonoclonal antibody[NCT02008357](ctgov:NCT02008357){#intref0220}Eli Lilly and CompanyFeb 14Apr 20[NCT01127633](ctgov:NCT01127633){#intref0225}Eli Lilly and CompanyDec 10Nov 18[NCT01900665](ctgov:NCT01900665){#intref0230}Eli Lilly and CompanyJul 13Oct 18[NCT01760005](ctgov:NCT01760005){#intref0235}[∗](#tbl1fnlowast){ref-type="table-fn"}Washington University School of MedicineDec 12Dec 19TRx0237AntitauAnti-tau agent[NCT02245568](ctgov:NCT02245568){#intref0240}TauRx TherapeuticsAug 14Jan 17[NCT01689246](ctgov:NCT01689246){#intref0245}TauRx TherapeuticsJan 13Nov 15[NCT01689233](ctgov:NCT01689233){#intref0250}TauRx TherapeuticsOct 12May 16TTP488 (Azeliragon)Anti-amyloid, anti-inflammatoryAnti-amyloid RAGE antagonist[NCT02080364](ctgov:NCT02080364){#intref0255}TransTech PharmaApr 15Mar 18[^1][^2][^3]

2.2. Phase II {#sec2.2}
-------------

There are 45 agents in phase II of AD drug development being assessed in 52 clinical trials. The pipeline includes 12 symptomatic cognitive-enhancing agents and three agents addressing neuropsychiatric symptoms. There are 30 DMTs being studied in phase II drug development programs; 26 of these are small molecules and four are immunotherapies. Amyloid-related targets comprise the mechanism of action of nine of the 26 small molecules and all four of the immunotherapies. Forty-three percent of phase II DMTs have amyloid-targeting mechanisms of action. Sixteen agents have "other mechanisms" including ten putative neuroprotective agents and six addressing metabolic problems. There is one antitau agent in phase II and one stem cell program (with two trials) in phase II of development.

Phase II trials of symptomatic agents have a mean duration of 19.1 weeks and trials of DMTs in phase II have a mean duration of 49.5 weeks. On average, there are 67.1 subjects per arm in phase II trials of symptomatic treatments and 76.9 subjects per arm in trials of DMT agents.

Of the 52 trials for the 45 agents, 29 are industry-sponsored, four are sponsored by NIH, and 18 are sponsored by "other" entities such as academic medical centers and philanthropic foundations. One trial is jointly sponsored by NIH and industry.

[Table 2](#tbl2){ref-type="table"} shows the agents in phase II with their mechanism of action.Table 2Agents currently in phase II of AD drug development and their mechanism of action (as of 1/4/2016)AgentAgent mechanism classMechanism of actionClinicaltrials.gov IDSponsorStart dateEstimated end dateAdenosine triphosphateAntiamyloidInhibits amyloid misfolding and toxicity[NCT02279511](ctgov:NCT02279511){#intref0265}Fundació Clínic per la Recerca BiomèdicaNov 14Nov 16ANAVEX 2-73NeuroprotectiveSigma-1 receptor agonist[NCT02244541](ctgov:NCT02244541){#intref0270}Anavex Life Sciences Corp.Dec 14Oct 16AtomoxetineAntiamyloidAdrenergic uptake inhibitor[NCT01522404](ctgov:NCT01522404){#intref0275}Emory UniversityMar 12Dec 17AZD0530 (saracatinib)AntiamyloidKinase inhibitor[NCT02167256](ctgov:NCT02167256){#intref0280}Yale UniversityDec 14Dec 16BAN2401AntiamyloidMonoclonal antibody[NCT01767311](ctgov:NCT01767311){#intref0285}EisaiDec 12Jul 18BenfotiamineMetabolicAntioxidant[NCT02292238](ctgov:NCT02292238){#intref0290}Burke Medical Research InstituteNov 14Nov 19BI 409306NeuroprotectivePDE9 inhibitor[NCT02240693](ctgov:NCT02240693){#intref0295}Boehringer IngelheimJan 15Jun 17[NCT02337907](ctgov:NCT02337907){#intref0300}Boehringer IngelheimJan 15May 17Byrostatin 1NeuroprotectiveProtein kinase C inhibitor[NCT02431468](ctgov:NCT02431468){#intref0305}Neurotrope BioscienceJul 15Apr 17CilostazolNeuroprotectivePDE3 antagonist[NCT02491268](ctgov:NCT02491268){#intref0310}National Cerebral and Cardiovascular CenterJul 15Jul 18CNP520AntiamyloidBACE inhibitor[NCT02576639](ctgov:NCT02576639){#intref0315}NovartisAug 15Mar 16CPC-201Neurotransmitter basedCholinesterase inhibitor + peripheral cholinergic antagonist[NCT02185053](ctgov:NCT02185053){#intref0320}Chase Pharmaceuticals CorporationJul 14Mar 16[NCT02434666](ctgov:NCT02434666){#intref0325}Chase Pharmaceuticals CorporationJan 15Jul 16CrenezumabAnti-amyloidMonoclonal antibody[NCT01998841](ctgov:NCT01998841){#intref0330}GenentechDec 13Sep 20DAOIBNeurotransmitter basedNMDA enhancer[NCT02103673](ctgov:NCT02103673){#intref0335}Chang Gung Memorial HospitalFeb 14Sep 16[NCT02239003](ctgov:NCT02239003){#intref0340}Chang Gung Memorial HospitalJan 12Jul 16E2609Anti-amyloidBACE inhibitor[NCT02322021](ctgov:NCT02322021){#intref0345}EisaiNov 14Jul 19ExenatideMetabolicGlucagon-like peptide 1 receptor agonist[NCT01255163](ctgov:NCT01255163){#intref0350}[National Institute on Aging (NIA)](http://National%20Institute%20on%20Aging%20(NIA)){#interref0015}Nov 10Dec 18Formoterol A&BNeuroprotectiveBeta-2 adrenergic receptor agonist[NCT02500784](ctgov:NCT02500784){#intref0355}Palo Alto Veterans Institute for ResearchJan 15Jul 16hUCB-MSCsNeuroprotectiveStem cell therapy[NCT02054208](ctgov:NCT02054208){#intref0360}Medipost CoFeb 14Feb 18[NCT01547689](ctgov:NCT01547689){#intref0365}Affiliated Hospital to Academy of Military Medical Sciences, Beijing, ChinaMar 12Dec 16Insulin detemirMetabolicInsulin[NCT01595646](ctgov:NCT01595646){#intref0370}University of WashingtonNov 11Sep 15Insulin glulisineMetabolicInsulin[NCT02503501](ctgov:NCT02503501){#intref0375}HealthPartners Institute for Education and ResearchAug 15Sep 17JNJ-54861911Anti-amyloidBACE inhibitor[NCT02406027](ctgov:NCT02406027){#intref0380}JanssenJul 15Jun 24[NCT02260674](ctgov:NCT02260674){#intref0385}JanssenNov 14Jun 16LevetiracetamNeurotransmitter basedAnticonvulsant[NCT02002819](ctgov:NCT02002819){#intref0390}University of California, San FranciscoJun 14Jun 17LiraglutideMetabolicGlucagon-like peptide 1 receptor agonist[NCT01843075](ctgov:NCT01843075){#intref0395}Imperial College LondonJan 14Jan 17LithiumNeurotransmitter basedIon channel modulator[NCT02129348](ctgov:NCT02129348){#intref0400}New York State Psychiatric InstituteJun 14Apr 19MetforminMetabolicInsulin sensitizer[NCT01965756](ctgov:NCT01965756){#intref0405}University of PennsylvaniaJan 13Dec 16Methylene BlueAnti-tauTau inhibitor; neuronal stimulant[NCT02380573](ctgov:NCT02380573){#intref0410}University of Texas Health Science Center at San AntonioJul 15Jul 18MK-7622Neurotransmitter basedMuscarinic agonist[NCT01852110](ctgov:NCT01852110){#intref0415}MerckOct 13Apr 20MK-8931Anti-amyloidBACE inhibitor[NCT01739348](ctgov:NCT01739348){#intref0420}MerckNov 12Jul 19NewGam 10% IVIGAnti-amyloidPolyclonal antibody[NCT01300728](ctgov:NCT01300728){#intref0425}Sutter HealthJan 11Nov 17ORM-12741Neurotransmitter basedAlpha-2c adrenergic receptor antagonist[NCT02471196](ctgov:NCT02471196){#intref0430}Orion CorporationJun 15Feb 17PF-05212377 (SAM 760)Neurotransmitter based5-HT6 receptor antagonist[NCT01712074](ctgov:NCT01712074){#intref0435}PfizerNov 12Dec 15Pimavanserin tartrateNeurotransmitter based5-HT2A inverse agonist[NCT02035553](ctgov:NCT02035553){#intref0440}AcadiaNov 13Jun 16PiromelatineNeurotransmitter basedMelatonin receptor agonist; 5-HT 1A and 1D receptor agonist[NCT02615002](ctgov:NCT02615002){#intref0445}Neurim PharmaceuticalsNov 15Dec 17PQ912Anti-amyloid, anti-inflammatoryGlutaminyl-peptide cyclotransferase inhibitor[NCT02389413](ctgov:NCT02389413){#intref0450}Probiodrug AGMar 15Oct 16PXT00864Neurotransmitter basedCombination of acamprosate and baclofen[NCT02361242](ctgov:NCT02361242){#intref0455}Pharnext, SASJun 13Dec 15RasagilineNeuroprotectiveMonoamine oxidase B inhibitor[NCT02359552](ctgov:NCT02359552){#intref0460}The Cleveland ClinicFeb 15Dec 16RiluzoleNeuroprotectiveGlutamate receptor antagonist; glutamate release inhibitor[NCT01703117](ctgov:NCT01703117){#intref0465}Rockefeller UniversityApr 13Nov 17RPh201NeuroprotectiveG-protein coupled receptor antagonist[NCT01513967](ctgov:NCT01513967){#intref0470}Regenera PharmaJan 12Dec 16S47445 (formerly CX1632)Neurotransmitter basedAMPA receptor agonist; nerve growth factor stimulant[NCT02626572](ctgov:NCT02626572){#intref0475}Institut de Recherches Internationales ServierFeb 15Sep 17Sagramostim (GM-CSF)Anti-amyloidGranulocyte colony stimulator; amyloid removal[NCT01409915](ctgov:NCT01409915){#intref0480}University of Colorado, DenverMar 11Jul 16Sembragiline (RO4602522)Neurotransmitter basedMonoamine oxidase B inhibitor[NCT01677754](ctgov:NCT01677754){#intref0485}Hoffmann-La RocheNov 12Jun 15Simvastatin + L-Arginine + TetrahydrobiopterinNeuroprotectiveHMG-CoA reductase inhibitor and antioxidant[NCT01439555](ctgov:NCT01439555){#intref0490}University of Massachusetts, WorcesterNov 11Dec 16SUVN-502Neurotransmitter based5-HT6 antagonist[NCT02580305](ctgov:NCT02580305){#intref0495}Suven Life SciencesSep 15Jun 17T-817 MANeuroprotectiveNeurotrophic agent[NCT02079909](ctgov:NCT02079909){#intref0500}ToyamaMar 14Mar 17TelmisartanNeuroprotectivePPAR-gamma agonist[NCT02085265](ctgov:NCT02085265){#intref0505}Sunnybrook Health Sciences CentreMar 14Aug 18UB-311Anti-amyloidMonoclonal antibody[NCT02551809](ctgov:NCT02551809){#intref0510}United NeuroscienceOct 15Jan 18VX-745NeuroprotectiveP38 mitogen-activated protein kinase inhibitor[NCT02423200](ctgov:NCT02423200){#intref0515}EIP PharmaApr 15Jan 16[NCT02423122](ctgov:NCT02423122){#intref0520}EIP PharmaApr 15Sep 16[^4][^5]

2.3. Phase I {#sec2.3}
------------

There are 24 agents in phase I AD drug-development programs. Of these, three are symptomatic agents, 13 are small molecule DMTs, and eight are DMT immunotherapies. Five of the 13 small molecules and seven of the eight immunotherapies address amyloid-related mechanisms (57% of the DMT mechanisms). One tau-directed antibody and one tau-related small molecule are included in the AD phase I pipeline. Five neuroprotective agents and two metabolic agents are being assessed.

Of the 27 trials of phase I agents, 20 are sponsored by the biopharma industry, two are funded by NIH, one is jointly supported by NIH and industry, and four are funded through other mechanisms.

[Table 3](#tbl3){ref-type="table"} shows the agents in phase I with their mechanism of action.Table 3Agents currently in phase I of development and their mechanism of action (as of 1/4/2016)AgentAgent mechanism classMechanism of actionClinicaltrials.gov IDSponsorStart dateEstimated end dateAADvac1Anti-tauMonoclonal antibody directed at Tau epitope[NCT02031198](ctgov:NCT02031198){#intref0530}Axon NeuroscienceJan 14Sep 17ABT-957NeuroprotectiveCalpain inhibitor[NCT02220738](ctgov:NCT02220738){#intref0535}AbbVieSep 14Jun 16[NCT02573740](ctgov:NCT02573740){#intref0540}AbbVieNov 15Nov 16AducanumabAnti-amyloidMonoclonal antibody[NCT01677572](ctgov:NCT01677572){#intref0545}BiogenOct 12Oct 19[NCT02434718](ctgov:NCT02434718){#intref0550}BiogenMay 15Jul 17Allopregnanolone injectionNeuroprotectiveGABA receptor modulator[NCT02221622](ctgov:NCT02221622){#intref0555}University of Southern CaliforniaAug 14Mar 17BI 409306Neurotransmitter basedPDE 9A inhibitor[NCT02392468](ctgov:NCT02392468){#intref0560}Boehringer IngelheimApr 15Oct 16Bisnorcymserine (BNC)Neurotransmitter basedButyrylcholinesterase inhibitor[NCT01747213](ctgov:NCT01747213){#intref0565}[National Institute on Aging (NIA)](http://National%20Institute%20on%20Aging%20(NIA)){#interref0010}Nov 12Jul 17CrenezumabAnti-amyloidMonoclonal antibody[NCT02353598](ctgov:NCT02353598){#intref0570}GenentechFeb 15Sep 17CT1812Anti-amyloidSigma-2 receptor modulator; reduces amyloid toxicity[NCT02570997](ctgov:NCT02570997){#intref0575}Cognition TherapeuticsSep 15Jun 16GC021109Anti-inflammatory, neuroprotectiveAnti-inflammatory[NCT02386306](ctgov:NCT02386306){#intref0580}GliaCureFeb 15Oct 15Insulin Aspart IntranasalMetabolicInsulin[NCT02462161](ctgov:NCT02462161){#intref0585}Wake Forest School of MedicineMay 15Dec 16JNJ-54861911Anti-amyloidBACE inhibitor[NCT02360657](ctgov:NCT02360657){#intref0590}JanssenFeb 15Sep 15KHK6640Anti-amyloidAmyloid aggregation inhibitor[NCT02127476](ctgov:NCT02127476){#intref0595}Kyowa Hakko Kirin PharmaJul 14Feb 17[NCT02377713](ctgov:NCT02377713){#intref0600}Kyowa Hakko Kirin PharmaMar 15Dec 16LorazepamNeurotransmitter basedBenzodiazepam[NCT01780519](ctgov:NCT01780519){#intref0605}Mayo ClinicJan 13Sep 16Lu AF20513Anti-amyloidMonoclonal antibody[NCT02388152](ctgov:NCT02388152){#intref0610}H. Lundbeck A/SMar 15Dec 16LY2599666 + SolanezumabAnti-amyloidMonoclonal antibody combination[NCT02614131](ctgov:NCT02614131){#intref0615}Eli Lilly and CompanyDec 15Jul 17LY3002813Anti-amyloidMonoclonal antibody[NCT01837641](ctgov:NCT01837641){#intref0620}Eli Lilly and CompanyMay 13Sep 16LY3202626Anti-amyloidUndisclosed mechanism[NCT02323334](ctgov:NCT02323334){#intref0625}Eli Lilly and CompanyDec 14Feb 16MEDI1814Anti-amyloidMonoclonal antibody[NCT02036645](ctgov:NCT02036645){#intref0630}AstraZenecaFeb 14Oct 16NGP 555Anti-amyloidGamma-secretase modulator[NCT02534480](ctgov:NCT02534480){#intref0635}NeuroGenetic PharmaceuticalsMar 15Nov 15OxaloacetateMetabolicMitochondrial enhancer[NCT02593318](ctgov:NCT02593318){#intref0640}University of Kansas Medical CenterOct 15Oct 17PF-06751979Anti-amyloidUndisclosed mechanism[NCT02509117](ctgov:NCT02509117){#intref0645}PfizerJul 15Jul 16S-EquolNeuroprotectiveEstrogen receptor beta agonist[NCT02142777](ctgov:NCT02142777){#intref0650}University of Kansas Medical CenterJul 14Dec 16TelmisartanNeuroprotectivePPAR-gamma agonist[NCT02471833](ctgov:NCT02471833){#intref0655}Emory UniversityApr 15Mar 18TPI-287Anti-tauMicrotubule protein modulator[NCT01953705](ctgov:NCT01953705){#intref0660}University of California, San FranciscoMay 14Mar 19[^6][^7]

2.4. Biomarkers {#sec2.4}
---------------

Biomarkers are playing an increasingly important role in clinical trials of DMTs. Not all trials on [clinicaltrials.gov](http://clinicaltrials.gov){#intref0035} state if biomarkers are included in their trials or discuss the type of biomarkers included, and we discuss the percent of trials that describe which biomarkers are included ([Table 4](#tbl4){ref-type="table"}). In current phase III trials, measurement of cerebrospinal fluid (CSF) amyloid beta protein (Aβ) is the most commonly used biomarker (27.7% of trials reporting use of biomarkers), followed by volumetric magnetic resonance imaging (MRI; 25%), CSF tau, and amyloid positron emission tomography (PET; 22.2% each), fluorodeoxyglucose (FDG) PET (19.4%), plasma amyloid (8.3%), and tau PET (2.7%). Phase II biomarkers include CSF amyloid (25%), CSF tau (21.2%), volumetric MRI (15.4%), FDG PET (11.5%), amyloid PET (9.6%), plasma amyloid (5.8%), and plasma tau (3.8%).Table 4Percent of trials with specific biomarkers included (this calculation is based on the number of trials in which the inclusion of biomarkers is described)Biomarker% of trialsPhase IIIPhase II1. CSF amyloid27.7252. CSF tau22.221.13. FDG-PET19.411.54. vMRI2515.35. Plasma amyloid8.35.76. Plasma tau03.87. Amyloid PET22.29.68. Tau PET2.70

3. Discussion {#sec3}
=============

This analysis of [clinicaltrials.gov](http://clinicaltrials.gov){#intref0040} reveals that there are relatively few agents in AD drug-development programs. The high failure rate in AD drug development and the small number of drugs being assessed suggest that the emergence of a repertoire of AD agents that could be tailored to fit the individual needs of patients is unlikely. The small number of agents in phase I is especially concerning as this phase is the major source of drugs for later stage development. A few repurposed agents can enter at phase II or phase III, but these agents generally have limited patent lives or limited intellectual property opportunities and do not comprise a major source of new candidate compounds [@bib8]. Likewise, immunotherapies often begin in phase I/phase II with patients diagnosed with AD to avoid the risk of permanently altering the immune system of normal volunteers but, as can be seen, there are only a few such agents entering the drug-development pipeline. Overall, the AD ecosystem of AD drug development must be altered to yield more targets and more candidate therapies if a robust pipeline of therapies is to be established.

Other reviews of AD drug development have led to similar conclusions as those presented here. The comprehensive 2010 review by Mangialasche et al. [@bib9] showed that new approaches to cholinergic therapy and many antiamyloid trials were being pursued. There were more agents directed toward tau-related targets in the 2010 pipeline review; most of these have since failed. [Fig. 1](#fig1){ref-type="fig"} is similar to the visualization approach used by Mangialasche et al. [@bib9] and can be used to compare changes over a 6-year period. Similarly, Cummings et al [@bib3] found---using a similar strategy to that used in the current review---that there were relatively few drugs being assessed and that the overall failure rate for AD drug development was a dramatic 99.6%. They also noted that no new novel drugs for AD had been approved since 2003.

We compared AD drug development with oncology drug development to provide a perspective on the observed numbers. In the 2014--2015 period, 135 trials were registered for AD, whereas 4976 trials were registered for cancer (these figures were generated from [clinicaltrials.gov](http://clinicaltrials.gov){#intref0045} using the same search terms as used in the reviewed AD trials and agents). This indicates that the number of agents in trials is much larger for cancer than for AD and the likelihood of finding effective therapies is greater. This disparity likely reflects several influences including the greater success of rate of cancer drug development (19.8% of development programs succeed in cancer vs less than 1 percent of AD drugs [@bib3], [@bib10]). Thirty-one percent of FDA new drug approvals for 2015 were for oncology agents [@bib11]. The low success rate of AD drug development discourages pharmaceutical companies from pursuing research in this area and reduces the enthusiasm of venture capitalists for investing in biotechnology companies whose products address AD-related targets. As a result, fewer targets are identified, and fewer candidate agents discovered and developed. The biological understanding of cancer has identified more putative targets. Greater insight into AD pathophysiology may lead to more target identification and more opportunities to develop mechanistically informed treatments.

The AD drug-development pipeline has amyloid beta-protein production or removal as it major focus. Across all phases, 56% of DMTs have an amyloid-related target. Monoclonal antibodies and BACE inhibitors comprise the two most developed pathways in the current pipeline. Monoclonal antibody approaches have instituted two major changes in drug development based on experiences with the failure of bapineuzumab: (1) patient populations with more mild disease are now the focus of trials [@bib12]; (2) amyloid imaging or CSF Aβ measures are performed at baseline to insure that patients have the target pathology for antiamyloid therapies [@bib13], [@bib14]. BACE inhibitors have included measures of CSF Aβ to demonstrate target engagement and show that the putative goal of reduction is being achieved [@bib15]. Demonstration of target engagement early in the development process makes it more likely---without proving---that clinical benefits may follow long-term therapy [@bib16].

Tau is a relatively unexploited target with only four agents in the pipeline devoted to tau-related pathophysiology. The availability of tau imaging and the consistent relationships shown between tau signals on imaging and the clinical state of the individual indicate that tau is an important target for drug development and that tau imaging may serve as a useful biomarker to help guide drug development [@bib17], [@bib18], [@bib19], [@bib20]. Tau protein is being targeted in trials of experimental therapies for tauopathies including frontotemporal dementia and progressive supranuclear palsy, and learnings from these trials may inform treatment of tau pathology in AD.

Thirty-eight percent of DMTs are small molecule agents that address neuroprotection or metabolic targets such as insulin resistance or PPAR-gamma--related mechanisms. These approaches are more well represented in phase II than phase III and suggest that the repertoire of targets is broadening for agents in the AD pipeline.

Symptomatic agents represent an important part of the AD drug-development pipeline. Improvement in cognitive and behavioral symptoms is a major goal of treatment and is achieved only partially by current therapies. There are 25 symptomatic cognitive enhancers or neuropsychiatric agents in the current pipeline comprising 27% of the entire drug-development pipeline. Symptomatic treatments are especially well represented in phase II where they comprise 33% of all agents at that stage of development. These agents enhance cholinergic signaling or capitalize on noncholinergic serotonergic, sigma-1, phosphodiesterase, or N-methyl-D-asparate (NMDA) mechanisms.

There is increasing recognition that combination therapies may be warranted to address the complex biology of AD [@bib21]. Combinations have found success in other complex diseases such as cancer, tuberculosis, and human immunodeficiency virus infections. There are few examples in the AD pipeline of combination of agents in trials; ALZT-OP1a/1b is a combination approach at phase III, simvastatin/l-arginine/tetrahydrobiopterin is being assessed at phase II; and LY2599666 plus solanezumab is being tested in phase I. In addition to these pharmacodynamics combinations, AVP-786 is a pharmacokinetic combination of dextromethorphan and the CYP2D6 inhibitor, quinidine, used to elevate levels of dextromethorphan. Overall, combinations comprise a limited aspect of the AD drug-development pipeline and represent an important future direction of drug development.

Currently, DMTs spend relatively little time in phase II (average 49 weeks) and involve a small number of patients per trial arm (average 67). Given the 100% failure rate of DMTs in phase III, more thorough exploration of these agents in phase II may benefit drug-development programs and the likelihood of phase III success.

Biomarkers play an increasingly important role in AD drug development. The demonstration that approximately 25% of patients included in trials of clinical-diagnosed AD do not have elevated levels of brain amyloid when studied with amyloid imaging indicated that use of biomarkers was critical in identifying a population with the target pathology in trials of antiamyloid agents and that have an accurate diagnosis for inclusion of trials of other agents [@bib13], [@bib14]. Nearly, all current trials of antiamyloid agents require positive amyloid imaging at baseline to insure accurate diagnosis and include amyloid imaging as an outcome to determine the effect of the therapeutic intervention on the brain plaque burden. Target engagement biomarkers are now more commonly used in drug-development programs such as those for BACE inhibitors to show that a biological effect has been achieved and that clinical effects could reasonably be expected. CSF measurements of amyloid and tau, volumetric MRI, and amyloid PET are used approximately equally commonly in DMT programs; no consensus on a single biomarker or combination of biomarkers as optimal to meet regulatory expectations for biomarker data has emerged.

Of trials across all phases of AD drug development, 74% are completely or partially sponsored by the biopharmaceutical industry. Given the prominent role of industry in AD drug development, legislative incentives to attract the pharmaceutical and biotechnology industries to AD may be one of the means of enhancing the number of candidate agents entering the AD pipeline. Increased federal funding to augment the small number of trial sponsored by NIH (9% with total or partial NIH funding) might also enhance the pipeline. Funding for basic science through NIH or venture capital support of biotechnology companies is needed to identify new targets and generate new candidate therapies. Similarly, new strategies in drug development including more emphasis on demonstrating target engagement in early stage development and use of adaptive designs to support clinical trials decision making may accelerate the drug development process and decrease the number of late-stage failures of agents in the pipeline.

This analysis is based on a review of [clinicaltrials.gov](http://clinicaltrials.gov){#intref0050} and is subject to the limitations of that database. While inclusive of all trials in the United States and many non-US countries, it may not include all trials being conducted in other countries and the list of drugs we discuss may not be comprehensive from an international perspective. In addition, not all phase I trials are included on [clinicaltrials.gov](http://clinicaltrials.gov){#intref0055}, especially when they are conducted in non-US phase I units, and we may underestimate the total number of agents being assessed in phase I. There is sometimes a lag in listing trials on [clinicaltrials.gov](http://clinicaltrials.gov){#intref0060}, and the lists included here may not be fully comprehensive for the time window assessed. These limitations will affect some details of the analysis but not the overall view of the landscape of AD drug development.

In summary, the AD drug-development pipeline is modest in size and strikingly smaller than very active areas of experimental therapeutics such as cancer. The phase I candidate pool is particularly small and bodes poorly for a compelling set of agents to be advanced to phase II and III. Amyloid is the most common pharmaceutical target, reflecting the greater understanding of the pathophysiology of this peptide. Symptomatic agents are making progress toward treatment of both cognitive and behavioral symptoms of AD. Biomarkers are being integrated into DMT development programs. Every source of compounds including academic medical centers, NIH, philanthropic funders, biotechnology, and pharmaceutical companies should be attracted to AD drug development to create a larger pipeline and a greater chance of success of AD drug development.Research in context1.Systematic Review: Drug development for Alzheimer\'s disease (AD) proceeds through three phases (I, II, III). By assessing the number of agents in each phase as recorded on [clinicaltrials.gov](http://clinicaltrials.gov){#intref0065}, one can determine current AD drug development activity to assess how many agents are being studied, the success of the research, and how the number of new drugs can be increased.2.Interpretation: Our data show that there are 93 drugs in development for treatment of AD. There are more drugs in phase II (45) than in phase III (24) or phase I (24). The small number of phase I compounds suggest that there is insufficient drug discovery activity to supply new agents for testing in clinical trials.3.Future directions: This review of the AD drug-development pipeline provides insight into the state of AD drug development and encourages review of how best to amplify the drug discovery/development ecosystem.
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[^1]: Abbreviations: BACE, beta-site amyloid precursor protein cleaving enzyme; PPAR, peroxisome proliferator-activated receptor; RAGE, receptor for advanced glycation end products.

[^2]: NOTE. Twenty-four agents in 36 phase III clinical trials currently ongoing (active, not recruiting, and active, recruiting) as of January 4, 2016 according to [clinicaltrials.gov](http://clinicaltrials.gov){#intref0260}.

[^3]: Same trial studying gantenerumab and solanezumab independently.

[^4]: Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; BACE, beta-site amyloid precursor protein cleaving enzyme. GM-CSF, granulocyte-macrophage colony-stimulating factor; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme; hUCB-MSCs, human umbilical cord-derived mesenchymal stem cells; IVIG, intravenous immunoglobulin; NMDA, N-methyl-D-aspartate; PDE, phosphodiesterase; PPAR, peroxisome proliferator-activated receptor.

[^5]: NOTE. Forty-six agents in 52 phase II clinical trials currently ongoing (active, not recruiting and active, recruiting) as of January 4, 2016 according to [clinicaltrials.gov](http://clinicaltrials.gov){#intref0525}.

[^6]: Abbreviations: BACE = beta-site amyloid precursor protein cleaving enzyme; GABA = gamma-aminobutyric acid; PDE = phosphodiesterase; PPAR = peroxisome proliferator-activated receptor.

[^7]: NOTE. Twenty-four agents in 27 phase I clinical trials currently ongoing (active, not recruiting, and active, recruiting) as of January 4, 2016, according to [clinicaltrials.gov](http://clinicaltrials.gov){#intref0665}.
